Three third-generation CDK inhibitors, palbociclib, ribociclib, and abemaciclib, have higher specificity to CDK4/6 than other members of the CDK family and have been translated into clinical use against advanced luminal breast cancer. Here, CDK4 is linked to breast cancer.